Hepatitis E

  • Hepatitis E virus (HEV), the major etiologic agent of enterically transmitted non-A, non-B hepatitis worldwide, is a spherical, non-enveloped, single stranded RNA virus that is approximately 32 to 34 nm in diameter.

  • Based on similar physicochemical and biologic properties, HEV has been provisionally classified in the Caliciviridae family; however, the organization of the HEV genome is substantially different from that of other caliciviruses and HEV may eventually be classified in a separate family.

Incubation period: Average 40 days
Range 15-60 days
Case-fatality rate: Overall, 1%-3%
Pregnant women, 15%-25%
Illness severity Increased with age
  • HEV is transmitted primarily by the fecal-oral route and fecally contaminated drinking water is the most commonly documented vehicle of transmission.
  • Hepatitis E is most commonly recognized to occur in large outbreaks, HEV infection accounts for >50% of acute sporadic hepatitis in both children and adults in some high endemic areas.
  • Risk factors for infection among persons with sporadic cases of hepatitis E have not been defined. Unlike hepatitis A virus, which is also transmitted by the fecal-oral route, person-to-person transmission of HEV appears to be uncommon.
  • Nosocomial transmission, presumably by person-to-person contact, has been reported to occur.
  • Outbreaks of hepatitis E have occurred over a wide geographic area, primarily in developing countries with inadequate environmental sanitation.
  • The reservoir of HEV in these areas is unknown.
  • The occurrence of sporadic HEV infections in humans may maintain transmission during inter-epidemic periods, but a nonhuman reservoir for HEV is also possible.
  • Prevention of hepatitis E relies primarily on the provision of clean water supplies
  •  No products are available to prevent hepatitis E
  •  IG prepared from plasma collected in non-HEV-endemic areas is not effective in preventing clinical disease during hepatitis E outbreaks and the efficacy of IG prepared from plasma collected in HEV-endemic areas is unclear
 

[ Home ] [ OLCODIBS]    [ E-mail ]   [ Homepages ]  [ Protocols ]  [ Forums ]

Copyright ©2001 eBioinfogen Innovatives. All Rights Reserved
editor@ebioinfogen.com